Trials / Active Not Recruiting
Active Not RecruitingNCT05873205
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Isatuximab | All participants enrolled on the study will receive isatuximab intravenously as a single agent |
Timeline
- Start date
- 2023-07-21
- Primary completion
- 2027-06-29
- Completion
- 2027-06-29
- First posted
- 2023-05-24
- Last updated
- 2026-04-02
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05873205. Inclusion in this directory is not an endorsement.